In order to discover and recognize the influential figures and advanced models who have made outstanding contributions to China’s economic development since the 70th anniversary of the founding of the People’s Republic of China, and timely promote the practitioners of “craftsmanship spirit” and “Chinese Dream”, on December 28-29, 2019, The 2019 China Economic Development Summit Forum and Annual Meeting of China’s Economic Influential People will be held in Beijing, sponsored by China Business Newspaper, China Business Magazine, Enterprise Research Institute of China Academy of Management Sciences, and China Circulation Research Institute of Capital University of Economics and Business. After being recommended by various professional media, authoritative institutions and industry authorities, and strictly reviewed by the organizing committee, Guo Xia, the founder of Venturepharma Medicine, has been shortlisted as a candidate for the “Top 10 Innovative Figures of China’s Economy in 2019”.
The expanded meeting of the review committee for the China Economic Figure of the Year was held. At the review committee meeting, relevant experts and leaders gave high praise to Mr. Guo and Venturepharma Pharmaceutical Holdings. During its development, Venturepharma Pharmaceutical Holdings has been committed to enabling Chinese people to enjoy and afford the world’s most advanced medicines and their pursuit of health and beauty, making an extraordinary impact on improving China’s health cause! He is the most innovative entrepreneur in China’s health industry and the first Chinese company to acquire NASDAQ American Biomedical Company.
Guo Dong has led the research and development of innovative drugs in China for 11 years, won the first place in the application of innovative drugs in China for 10 years in a row, and was awarded the title of national model Worker and the National May Day Labor Medal by The State Council. Outstanding Entrepreneur and other honorary titles issued by The State Council.
Guo Dong won the top ten economic management figures in 2005. He has been named “China’s most Promising Businessman in the future” by Fortune Magazine of the United States, and has won the only “Young Entrepreneur” award in China selected by 10 organizations (Hong Kong) including Asia Week, and the title of “Special Contribution Award of the State Food and Drug Administration”. Top 10 leading figures in China’s pharmaceutical industry. With innovative thinking, innovative mode and innovative concept, innovation is the soul of a nation and the inexhaustive driving force for the prosperity of a country. With years of entrepreneurial experience, keen insight and foresight to the market, Guo Dong has become the leading figure in the industry. It has made outstanding contributions to the healthy development of today’s people, made entrepreneurs with a sense of social responsibility by drinking water, promoted employment, improved people’s livelihood, and helped enterprises develop and expand by promoting brands. The 2019″ Top Ten Innovative People of China’s Economy “declared by Chairman Guo Xia was voted by secret ballot at the review work meeting of the jury today. Venturepharma Pharmaceutical Holdings successfully passed the re-examination of the expert review committee with a high vote rate of 67% and has now been officially recommended to the review committee as one of the “Top Ten Innovative Figures of China’s Economy in the Year”.
Judge’s comments: Chairman Guo Xia has been awarded the national Model Worker for more than 20 years in the global science and technology campaign, the most potential businessman evaluated by the American Fortune, and the Global Innovative entrepreneur by the British Chamber of Commerce. He is a famous warrior in the Asian pharmaceutical industry and a benchmark and example for today’s entrepreneurs to learn from. Comrade Guo Xia is committed to innovation and has outstanding achievements. He is indeed a practitioner of the “craftsmanship spirit” and the “Chinese dream”, and an advanced model emerging in the process of China’s economic development.